Intravitreally administered anti–vascular endothelial growth factor (VEGF) agents have demonstrated efficacy in treating diabetic macular edema (DME) and improving visual acuity in phase 3 trials.1, 2, 3, 4, 5, 6 However, data generated outside clinical trials suggest that the frequent clinical evaluations and associated vision gains reported in clinical trial settings are difficult to achieve, to maintain, or both in routine clinical practice.7 Here, VEGFA is linked to diabetic macular edema.